Medications for Juvenile Polyarthritis

12 results

  • abrilada - adalimumab - afzb

    (Adalimumab-Afzb)
    Pfizer Laboratories Div Pfizer Inc
    Abrilada is a TNF blocker indicated for moderate-to-severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis (age 2+), Crohn's disease (age 6+), ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults.
    Medication Details
    Savings Programs
    1
    Drug Interactions

  • actemra - tocilizumab injection, solution, concentrate

    (Tocilizumab)
    Genentech, Inc.
    Actemra (tocilizumab) treats moderately to severely active rheumatoid arthritis, giant cell arteritis, SSc-associated interstitial lung disease, polyarticular and systemic juvenile idiopathic arthritis (ages 2+), CAR T cell-induced cytokine release syndrome, and hospitalized COVID-19 patients requiring oxygen support or mechanical ventilation.
    Medication Details
    Drug Interactions

  • cimzia - certolizumab pegol

    (Certolizumab Pegol)
    Ucb, Inc.
    CIMZIA is a TNF blocker that treats moderately to severely active Crohn's disease, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and plaque psoriasis in adults, and polyarticular juvenile idiopathic arthritis in patients 2 years and older.
    Medication Details
    Drug Interactions

  • hadlima - adalimumab - bwwd solution

    (Adalimumab-Bwwd)
    Organon Llc
    HADLIMA is a TNF blocker for adults and children with moderately to severely active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis. Also indicated for juvenile idiopathic arthritis in patients 2 years and older.
    Medication Details
    Drug Interactions

  • kevzara - sarilumab injection, solution

    (Sarilumab)
    Sanofi-Aventis U.S. Llc
    Kevzara treats moderately to severely active rheumatoid arthritis in adults after inadequate DMARD response, polymyalgia rheumatica in adults after inadequate or intolerable corticosteroid therapy, and active polyarticular juvenile idiopathic arthritis in patients weighing 63 kg or more.
    Medication Details
    Drug Interactions

  • orencia - abatacept injection, powder, lyophilized, for solution

    (Abatacept)
    E.R. Squibb & Sons, L.L.C.
    Orencia treats moderately to severely active rheumatoid arthritis in adults, polyarticular juvenile idiopathic arthritis and psoriatic arthritis in patients 2 years and older, and prevents acute graft-versus-host disease in HSCT patients 2 years and older.
    Medication Details
    Drug Interactions

  • otrexup - methotrexate injection, solution

    (Methotrexate)
    Antares Pharma, Inc.
    Otrexup treats severe, active rheumatoid arthritis and polyarticular juvenile idiopathic arthritis in patients intolerant of or unresponsive to first-line therapy, and severe, recalcitrant, disabling psoriasis in adults unresponsive to other treatments. Not indicated for neoplastic diseases.
    Medication Details
    Drug Interactions

  • rasuvo - methotrexate injection, solution

    (Methotrexate)
    Medexus Pharma Inc.
    Rasuvo treats severe, active rheumatoid arthritis in adults and polyarticular juvenile idiopathic arthritis in children who failed first-line therapy. Also indicated for severe, recalcitrant, disabling psoriasis in adults unresponsive to other treatments. Not for neoplastic diseases.
    Medication Details
    Drug Interactions

  • rinvoq - upadacitinib tablet, extended release

    (Upadacitinib)
    Abbvie Inc.
    RINVOQ is a JAK inhibitor indicated for adults and some pediatric patients with rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, non-radiographic axial spondyloarthritis, polyarticular juvenile idiopathic arthritis, and giant cell arteritis, generally after inadequate response to TNF blockers.
    Medication Details
    Drug Interactions

  • simponi aria - golimumab solution

    (Golimumab)
    Janssen Biotech, Inc.
    Simponi Aria is a TNF blocker that treats moderately to severely active rheumatoid arthritis (with methotrexate), active psoriatic arthritis, active ankylosing spondylitis, and active polyarticular juvenile idiopathic arthritis. RA and AS indications are for adults; PsA and pJIA are for patients 2 years and older.
    Medication Details
    Drug Interactions